A carregar...
Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy
BACKGROUND: We previously reported changes of body composition determined by dual-energy X-ray absorptiometry after treatment with ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. In that study, mean body weight was decreased by 3.5 kg (4.3% of the baseline value) after ipraglifloz...
Na minha lista:
| Publicado no: | J Clin Med Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elmer Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436566/ https://ncbi.nlm.nih.gov/pubmed/30937121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3785 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|